On its way out the door, the Biden Administration just released new guidelines for those seeking to license inventions made at the National Institutes of Health (NIH) that could lead to new “drugs, biologics (including vaccines) or devices for the prevention, diagnosis or treatment of human disease.” The administration has claimed this is being done “to expand patient access to products that emerge from NIH-owned inventions.” The guidelines apply to all licenses, exclusive and non-exclusive.
Recent Posts
- IPWatchdog Unleashed: Patents and the Future of the USPTO in Trump’s Second Term
- No Infringement Intended – The World Wrestling Federation’s Biggest Fight: A Look at Trademark Law and Global Brand Recognition
- Other Barks & Bites for Friday, February 7: CAFC Rejects Untimely Expert Testimony and Reassigns Case; CJEU Clarifies Online Marketplace Responsibilities Under GDPR; and IPWATCHPUPPIES ARE ON THE WAY!
- Commissioner for Patents Takes ‘Fork in the Road’ and Resigns from USPTO
- Reflections from an Inventor on the Return to Office Mandate for PTAB Judges